Analysis of the value and safety of thyroid-stimulating hormone in the clinical efficacy of patients with thyroid cancer

Table 1 Comparison of general information of each group (mean ± SD)

Group	Gender		Age (yr)	BMI (kg/m2)
	Male	Female
Control (n = 50)	22	28	53.25 ± 4.67	22.53 ± 3.67
Observation (n = 75)	38	37	51.34 ± 7.56	23.45 ± 4.23
χ2/t	0.584		1.594	1.255
P value	0.465		0.114	0.212

BMI: Body mass index.

Table 2 Comparison of soluble interleukin-2 receptor, interleukin-17, and interleukin-35 levels in each group (mean ± SD)

Group	sIL-2R (U/mL)		IL-17 (pg/mL)		IL-35 (pg/mL)
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Control (n = 50)	546.78 ± 36.67	435.26 ± 26.47	15.67 ± 2.44	10.27 ± 2.32	56.59 ± 7.23	68.78 ± 6.34
Observation (n = 75)	545.56 ± 34.12	359.56 ± 21.98	14.78 ± 2.65	6.79 ± 2.78	57.67 ± 7.15	94.98 ± 6.78
t	0.190	17.370	1.898	7.313	0.061	21.716
P value	0.849	< 0.001	0.060	< 0.001	0.951	< 0.001

sIL-2R: Soluble interleukin-2 receptor; IL-17: Interleukin-17; IL-35: Interleukin-35.

Table 3 Comparison of free triiodothyronine and free tetraiodothyronine levels in each group (mean ± SD)

Group	FT3 (ng/L)		FT4 (ng/L)
	Before treatment	After treatment	Before treatment	After treatment
Control (n = 50)	1.54 ± 0.23	2.23 ± 1.62	0.50 ± 0.16	0.89 ± 0.82
Observation (n = 75)	1.58 ± 0.27	3.12 ± 1.65	0.48 ± 0.11	1.56 ± 1.48
t	0.860	2.976	0.829	2.914
P value	0.392	0.004	0.409	0.004

FT₃: Free triiodothyronine; FT₄: Free tetraiodothyronine.

Table 4 Levels of CD3⁺, CD4⁺, and CD8⁺ in each group (mean ± SD)

Group	CD3+ (%)		CD4+ (%)		CD8+ (%)
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Control (n = 50)	53.56 ± 6.23	61.21 ± 6.32	25.87 ± 6.56	46.87 ± 6.76	39.98 ± 5.21	35.65 ± 9.67
Observation (n = 75)	52.45 ± 5.72	64.98 ± 6.56	26.78 ± 6.48	49.78 ± 5.65	41.34 ± 5.45	29.87 ± 9.87
t	1.026	3.194	0.765	2.606	1.391	3.233
P value	0.307	0.002	0.446	0.010	0.167	0.002

Table 5 Levels of CD44V6 and tumor supplied group of factor in each group (mean ± SD)

Group	CD44V6 (ng/mL)		TSGF (ng/mL)
	Before treatment	After treatment	Before treatment	After treatment
Control (n = 50)	512.45 ± 33.06	367.56 ± 24.67	74.35 ± 6.57	56.87 ± 5.76
Observation (n = 75)	513.52 ± 34.11	314.23 ± 20.12	72.78 ± 6.54	42.38 ± 5.21
t	0.174	12.719	1.312	14.600
P value	0.862	< 0.001	0.192	< 0.001

TSGF: Tumor supplied group of factor.

Table 6 Comparison of adverse reactions in each group, n (%)

Group	Rash	Osteoporosis	Recurrence	Overall incidence
Control (n = 50)	2 (4.00)	3 (6.00)	3 (6.00)	13 (26.00)
Observation (n = 75)	4 (5.33)	4 (5.33)	6 (8.00)	17 (22.67)
χ2	0.932	0.874	0.672	0.961
P value	0.733	0.812	0.944	0.111